26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)

2021 ◽  
Vol 85 (3) ◽  
pp. AB120
Author(s):  
Michael J. Cork ◽  
Diamant Thaçi ◽  
Lawrence Eichenfield ◽  
Peter D. Arkwright ◽  
Zhen Chen ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Safety Data ◽  
Severe Atopic Dermatitis ◽  
Efficacy And Safety ◽  
Open Label ◽  
Phase 3 ◽  
Term Efficacy ◽  
Open Label Extension ◽  
Extension Trial

scholarly journals Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study

2020 ◽  
Vol 131 (1-2) ◽  
pp. 219-228 ◽  
Author(s):  
Ulla Feldt-Rasmussen ◽  
Derralynn Hughes ◽  
Gere Sunder-Plassmann ◽  
Suma Shankar ◽  
Khan Nedd ◽  
...  
Keyword(s):  
Fabry Disease ◽  
Efficacy And Safety ◽  
Open Label ◽  
Phase 3 ◽  
Term Efficacy ◽  
Open Label Extension
Sign in / Sign up

Export Citation Format

Share Document